Systemic Fungal Infections

July 28, 2003

Schering-Plough reported positive results from a phase III trial investigating NOXAFIL (posaconazole suspension), a broad-spectrum antifungal for the treatment of invasive fungal infections. Results showed subjects successfully met the study's primary endpoint of a clinical and mycological response. The study enrolled 337 subjects with invasive fungal infections resistant or refractory to standard antifungal therapies. The company expects to submit an NDA shortly for NOXAFIL to the FDA and EMEA for marketing approval.<